Plain-English translation of NCT04728893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an oral medication taken once daily, to see if it can help people with certain blood cancers—particularly chronic lymphocytic leukemia, lymphoma, and Waldenström macroglobulinemia—that have come back or stopped responding to previous treatments. The study has two phases: first, doctors will figure out the best dose of this treatment, and then they will test it in larger groups of patients with different types of blood cancer to confirm it works safely and effectively.
Many patients with blood cancers eventually develop resistance to currently available medications, leaving them with few treatment options. This medication is designed to work through a different mechanism to help patients whose cancers no longer respond to standard therapies.
You likely qualify if…
You likely don't qualify if…
You would take as an oral tablet once every day for as long as the medication is helping your cancer and you are tolerating it well. The study involves regular visits with your doctor to check how well the treatment is working, monitor your blood counts and organ function, and watch for any side effects. Depending on which part of the study you join, you may be part of the dose-finding phase or one of the larger confirmation groups, and you would continue treatment until your cancer progresses or you need to stop for medical reasons.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States